anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To obtain a powdery material capable of isolating ultraviolet rays and infrared rays and transmitting visible rays by forming a selective light transmitting film on the surface of transparent mica. CONSTITUTION:A selective light transmitting film is formed on the surface of transparent mica such as muscovite. Preferred selective light transmitting film is one comprising (A) three layers of a transparent oxide having high refractive index, thin metallic film, and a transparent oxide having high refractive index, laminated successively in the described order, (B) two layers of a transparent oxide having high refractive index and a thin metallic film, laminated successively in the described order, or (C) two layers of a thin metallic film and a transparent oxide having high refractive index laminated in the described order, on the surface of mica. Suitable thin metallic film is a thin film of Au, Ag, Cu, Pd, etc., or an alloy thereof prepd. by sputtering and having 50-250Angstrom thickness, and suitable transparent oxide having high refractive index is thin film of TiO2, BaS, Ba titanate, etc., prepd. by sputtering and having 100-600Angstrom  thickness.
Dietary intervention: Written material on healthy diet during pregnancy, 2 virtual dietary counseling sessions given by a dietician. Otherwise basic care and counseling at maternity care clinics.
OBJECTIVE: The purpose of this study was to identify patients at particularly high risk for major amputation after emergent infrainguinal bypass to help tailor postoperative and long-term patient management.
METHODS: In the Vascular Quality Initiative, we identified 2126 patients who underwent emergent infrainguinal artery bypass. Two primary outcomes were investigated: major ipsilateral amputation above the ankle level during the index hospitalization and major amputation above the ankle at any time after emergent infrainguinal bypass surgery (perioperative and postdischarge combined). Binary logistic regression analysis was performed for each outcome using variables that achieved a univariable P value of ≤.10. We then determined which variables have a multivariable association for the outcomes as defined by a regression P value of ≤.05. A risk score was then created for the outcome of amputation after emergent infrainguinal bypass using weighted beta-coefficient. Variables with a multivariable P value of ≤.05 were included in the risk score and weighted based on their respective regression beta-coefficient in a point scale.
RESULTS: Overall, 17.1% of patients (368/2126) underwent major amputation at some point in follow-up after emergent infrainguinal artery bypass. The mean follow-up duration on the amputation variable was 261 days with the end point being time of amputation or time of last follow-up data on the amputation variable. Variables with a significant multivariable association (P < .05) with major amputation at any point after emergent infrainguinal arterial bypass were home status in top 10% (most deprived) of Area Deprivation Index, prior infrainguinal ipsilateral arterial bypass, prior ipsilateral endovascular arterial intervention, prosthetic bypass conduit, postoperative skin/soft tissue infection, and postoperative need to revise or thrombectomize bypass. Pertinent negatives on multivariable analysis included all baseline comorbidities, insurance status, race, and gender. There is steep progression in amputation rate ranging from 5% at scores of 0 and 1 to >60% for scores in of >10. Area under the curve analysis revealed a value of 0.706.
CONCLUSIONS: Patients living in the most disadvantaged socioeconomic neighborhoods have an increased risk of amputation after emergent infrainguinal arterial bypass independent of baseline comorbidities and perioperative events. Baseline comorbidities are not impactful regarding amputation rates after emergent infrainguinal bypass surgery. The need for bypass revision or thrombectomy during the index hospitalization is the most impactful factor toward amputation after emergency bypass. A risk score with quality accuracy has been developed to help identify patients at particularly high likelihood of limb loss, which may aid in counseling regarding heightened vigilance in postoperative and long-term follow-up care.
A procedure for the detection of malignant tumours using the agent δ-amino levulinic acid (hydrochloride) as a tumour marker is described. The tissue is exposed to the agent either by intravenous injection or by application of an unguent over superficial tumours. After a suitable time delay fluorescence is induced in the tissue using an excitation source, e.g. a laser. Cancer then emerges with a strong and specific fluorescence peak at 635 nm. By dividing this red peak intensity by the intensity of the blue-green autofluorescence from the tissue an improved demarcation is obtained and also immunity to variations in many experimental parameters.
The invention discloses an application of a compound regulator in regulating metabolic disorders caused by artemisinin sensitive/resistant plasmodium infection, in particular to artemisinin and felon euphorbia flavin, namely polymethoxyflavone enriched from an acetone layer of artemisinin industrial extraction waste material, which is compounded according to an optimal antimalarial ratio of 1:2 and is used for improving metabolic disorders caused by artemisinin sensitive/resistant plasmodium infection, wherein the plasmodium is plasmodium berghei (plasmodium falciparum) (a. sup.)/a. sup.) (a. sup.)) Plasmodium berghei ). The invention utilizes the specificity of the felwort to kill the artemisinin-resistant plasmodium, provides a potential artemisinin-resistant small-molecule inhibitor for clinic, and can be developed into effective improvement of artemisinin resistance by compounding with artemisininModulators of drug resistance-related metabolic disorders caused by infection with Plasmodium venenatum.
Participants will be asked to achieve a pre-set, individualised points target for physical activity each week. Points are acquired through the completion of a minimum 10 minutes of activity, choosing from the extensive list of activities provided; for example, 10 minutes of jogging achieves 4.5 points, whereas 10 minutes of washing a car achieves 1.5 points. The target will be 35-40 points per week, which equates to approximately 6 points per day. Any combination of activity, duration and frequency can be selected.
Proleukin exists as biologically active, non-covalently bound microaggregates with an average size of 27 recombinant interleukin-2 molecules. The solubilizing agent, sodium dodecyl sulfate, may have an effect on the kinetic properties of this product.

The pharmacokinetic profile of Proleukin is characterized by high plasma concentrations following a short intravenous infusion, rapid distribution into the extravascular space and elimination from the body by metabolism in the kidneys with little or no bioactive protein excreted in the urine. Studies of intravenous Proleukin in sheep and humans indicate that upon completion of infusion, approximately 30% of the administered dose is detectable in plasma. This finding is consistent with studies in rats using radiolabeled Proleukin, which demonstrate a rapid (<1 min) uptake of the majority of the label into the lungs, liver, kidney, and spleen.

The serum half-life (T 1/2) curves of Proleukin remaining in the plasma are derived from studies done in 52 cancer patients following a 5-minute intravenous infusion. These patients were shown to have a distribution and elimination T 1/2 of 13 and 85 minutes, respectively.

Following the initial rapid organ distribution, the primary route of clearance of circulating Proleukin is the kidney. In humans and animals, Proleukin is cleared from the circulation by both glomerular filtration and peritubular extraction in the kidney.5-8 This dual mechanism for delivery of Proleukin to the proximal tubule may account for the preservation of clearance in patients with rising serum creatinine values. Greater than 80% of the amount of Proleukin distributed to plasma, cleared from the circulation and presented to the kidney is metabolized to amino acids in the cells lining the proximal convoluted tubules. In humans, the mean clearance rate in cancer patients is 268 mL/min.

The relatively rapid clearance of Proleukin has led to dosage schedules characterized by frequent, short infusions. Observed serum levels are proportional to the dose of Proleukin.
888,038. Medicinal tablets. TRIGGS, W. W. (Wander Co.). Dec. 16, 1959, No. 42823/59. Class 81 (1). A medicinal tablet, other than an implantation tablet, comprises a main body portion 11 with a recess 12 in at least one side thereof and an inlay portion 13 disposed in and substantially filling said recess and forming with said main body portion a unitary tablet. In order to achieve differential release of the medicaments contained in the two portions in the gastrointestinal tract, the granules of either or both of said portions may be enteric coated prior to the formation of the tablet and in one embodiment the inlay portion is enteric coated as a whole. Specified enteric coating materials are cellulose acetate phthalate, tolu balsam, carnauba wax, alcoholic shellac solutions and hydrogenated fats. In other embodiments the recess 12 may be undercut to an extent sufficient to afford mechanical anchorage of the inlay portion or the tablet may have two inlay portions, one on either side of the tablet. The tablets may be circular, triangular, rectangular or cylindrical. The examples described (a) an appetite depressant tablet which contains as active ingredients d-amphetamine sulphate and amobarbital; (b) a decongestant tablet in which the active ingredients are phenyl propanolamine hydrochloride, pyrilamine maleate and phenuramine maleate; and (c) a hypnotic tablet in which the active ingredients are pentobarbital and mephenesin.
Selected CHH patients will be vaccinated against varicella with Varilrix, one dose of 0,5 ml subcutaneously. If no response is documented to the first dose, the second dose of 0,5 ml can be administered.
The participants in this arm will receive the following drugs and dosages: adult: 500 mg azithromycin and 400 mg cefixime. Pediatric: oral 20 mg/kg azithromycin suspension once a day and oral 10 mg/kg cefixime. Patients will receive antibiotic treatment until defervescence and for 3 days afterwards.
The high mortality rates of acute lung injury and acute respiratory distress syndrome challenge the field to identify biomarkers and factors that can be exploited for therapeutic approaches. IL-22 is a cytokine that has antibacterial and reparative properties in the lung. However, it also can exacerbate inflammation and requires tight control by the extracellular inhibitory protein known as IL-22 binding protein (IL-22BP) (Il22ra2). This study showed the necessity of IL-22BP in controlling and preventing acute lung injury using IL-22BP knockout mice (Il22ra2-/-) in the bleomycin model of acute lung injury/acute respiratory distress syndrome. Il22ra2-/- mice had greater sensitivity (weight loss and death) and pulmonary inflammation in the acute phase (first 7 days) of the injury compared with wild-type C57Bl/6 controls. The inflammation was driven by excess IL-22 production, inducing the influx of pathogenic IL-17A+ γδ T cells to the lung. Interestingly, this inflammation was initiated in part by the noncanonical IL-22 signaling to macrophages, which express the IL-22 receptor (Il22ra1) in vivo after bleomycin challenge. This study further showed that IL-22 receptor alpha-1+ macrophages can be stimulated by IL-22 to produce a number of IL-17-inducing cytokines such as IL-1β, IL-6, and transforming growth factor-β1. Together, the results suggest that IL-22BP prevents IL-22 signaling to macrophages and reduces bleomycin-mediated lung injury.
Midazolam doses for sedation during ERCP. Initial dose of 2-3 mg and after ERCP start, 1-2 mg as additional doses. Maximum total dose 6-8 mg. ERCP performing doctor is responsible for dose ordination.
BACKGROUND: Comorbid chronic rhinosinusitis (CRS) remains unresolved for many people with cystic fibrosis (PwCF). While highly effective modulator therapy improves quality-of-life and symptom severity, the impact of this intervention and other factors associated with pursuing endoscopic sinus surgery (ESS) remains understudied.
METHODS: Adult PwCF + CRS were enrolled into a prospective, observational, multi-institutional study. Participants completed validated outcome measures to evaluate respiratory symptom severity, depression, headache, and sleep quality, as well as nasal endoscopy, sinus computed tomography (CT), and olfactory testing. Bivariate comparisons and regression modeling evaluated treatment cofactors, disease characteristics, and outcome measures associated with pursuing ESS.
RESULTS: Sixty PwCF were analyzed, including 24 (40%) who elected ESS. Pursuing ESS was associated with worse SinoNasal Outcome Test (SNOT-22) total, rhinologic, psychological, and sleep dysfunction domain scores; worse Patient Health Questionnaire-9-Revised depression scores; worse Pittsburgh Sleep Quality Index total scores; worse weight, role, emotion, and eating domain scores on the Cystic Fibrosis Questionnaire-Revised; more severe disease on nasal endoscopy; and lack of modulator therapy (all p < 0.050). Multivariable regression identified that worse SNOT-22 total score was associated with electing ESS (odds ratio [OR] 1.09, 95% confidence interval [CI] 1.02-1.16, p = 0.015) and elexacaftor/tezacaftor/ivacaftor (ETI) treatment (OR 0.04, 95% CI 0.004-0.34, p = 0.004) was associated with pursing medical therapy.
CONCLUSIONS: Worse sinonasal symptom burden, lack of ETI treatment, sleep quality, depression, and nasal endoscopy scores were associated with electing ESS, while lung disease severity and sinus CT scores were not. ETI use was associated with lower odds of pursuing ESS independent of sinonasal symptom burden.
Increased femoral anteversion (IFA) occurs when the top of the thigh bone tilts forward more than normal. Many healthy kids and teens aren't considered to have a problem with this as long as they show no symptoms, since it often corrects itself by the time they reach ages 12 to 14. However, experts believe this condition might lead to complications later in life. Research indicates that children with IFA may be more prone to issues like kneecap misalignment, knee pain, and even arthritis as they grow older. This is likely due to the way their knees bend differently when they walk. Kids with IFA often walk with their toes pointing inward, which increases their chances of tripping and falling. They may also experience pain that interferes with their daily activities. It is assumed that strengthening the hips and improving hip flexibility could help reduce the need for compensatory movements, ultimately lowering the risk of tripping, falling, and experiencing pain in everyday life. This study is a randomized controlled trial aimed at examining how ballet training influences knee movement-specifically knee flexion-during walking in children with idiopathic coxa antetorta. The goal is to determine whether ballet training enhances the children's overall mobility and how they feel about their ability to move. Additionally, the study seeks to find out how this training can be effectively incorporated into the daily routines of affected schoolchildren.
Spasticity is a hyperexcitability disorder that adversely impacts functional recovery and rehabilitative efforts after spinal cord injury (SCI). The loss of evoked rate-dependent depression (RDD) of the monosynaptic H-reflex is indicative of hyperreflexia, a physiological sign of spasticity. Given the intimate relationship between astrocytes and neurons, that is, the tripartite synapse, we hypothesized that astrocytes might have a significant role in post-injury hyperreflexia and plasticity of neighboring neuronal synaptic dendritic spines. Here, we investigated the effect of selective Rac1KO in astrocytes (i.e., adult male and female mice, transgenic cre-flox system) on SCI-induced spasticity. Three weeks after a mild contusion SCI, control Rac1wt animals displayed a loss of H-reflex RDD, that is, hyperreflexia. In contrast, transgenic animals with astrocytic Rac1KO demonstrated near-normal H-reflex RDD similar to pre-injury levels. Reduced hyperreflexia in astrocytic Rac1KO animals was accompanied by a loss of thin-shaped dendritic spine density on α-motor neurons in the ventral horn. In SCI-Rac1wt animals, as expected, we observed the development of dendritic spine dysgenesis on α-motor neurons associated with spasticity. As compared with WT animals, SCI animals with astrocytic Rac1KO expressed increased levels of the glial-specific glutamate transporter, glutamate transporter-1 in the ventral spinal cord, potentially enhancing glutamate clearance from the synaptic cleft and reducing hyperreflexia in astrocytic Rac1KO animals. Taken together, our findings show for the first time that Rac1 activity in astrocytes can contribute to hyperreflexia underlying spasticity following SCI. These results reveal an opportunity to target cell-specific molecular regulators of H-reflex excitability to manage spasticity after SCI.Significance Statement Spinal cord injury leads to stretch reflex hyperexcitability, which underlies the clinical symptom of spasticity. This study shows for the first time that astrocytic Rac1 contributes to the development of hyperreflexia after SCI. Specifically, astrocytic Rac1KO reduced SCI-related H-reflex hyperexcitability, decreased dendritic spine dysgenesis on α-motor neurons, and elevated the expression of the astrocytic glutamate transporter-1 (GLT-1). Overall, this study supports a distinct role for astrocytic Rac1 signaling within the spinal reflex circuit and the development of SCI-related spasticity.
The recommended method for consuming 3T Pu-erh tea is as follows: according to individual preferences, once a day, 8 g/time, or twice a day, 4 g/time, using a 300 mL stew cup; Steep the tea in 200 mL of boiling water for 60-90 seconds and consume. The tea can be brewed multiple times, replacing regular water intake. Ensure that the entirety of the liquid in the cup is consumed during each session.
Chronic Kidney Disease associated Pruritus (CKD-aP) in hemodialysis affects approximately 38% of our patients. It is not associated with any dermatological lesion other than the common scratching lesions, a consequence of the symptom itself. The causes associated with itching have been studied in various treatments. However, there is a relatively rare condition that involves 10% of hemodialysis patients, known as reactive perforating collagenosis. This is a pathological condition secondary to chronic hemodialysis therapy, where widespread itching develops, associated with a peculiar reactive dermatosis with perforation of the dermis and development of dermal-epidermal continuity solutions with extrusion of matrix components dermal. In this work we report our experience with a diagnosed case of this condition.
The hippotherapy program started with a physical therapy assessment to develop specific corrective movements to be practiced while riding the horse based on the direction of the spinal curvature. Interventions were performed by a licensed physical therapist experienced with hippotherapy at two local therapeutic riding centers. The participants received 15 sessions split into two phases over 10 weeks. In the first phase, during the first 5 weeks, they performed 30 minutes of walking and sitting trot training without a stirrup iron once a week. The frequency was then raised to twice a week for the rest of the treatment program. Before the start of the intervention, two familiarization sessions were given to clarify safety guidelines, riding mistakes, and create a riding rapport with the horse. The individuals wore protective helmets during each hippotherapy session and mounted on a moving horse on walk and/or trot performing different positions, namely forward astride, side sitting, backward astride, sometimes with transitions between positions and often while the horse was moving. To restore normal alignment of the spine, participants were also asked to ride without holding on with their hands to perform self-correction movements. Examples of these movements include raising both arms high to decrease the degree of thoracic kyphosis, bending the upper trunk towards the convex side of the curve, raising the arm on the concave side with scapular adduction to level both shoulders. To correct pelvic obliquity, a small pad was put under the hip on the side of the lumbar convexity. Under the instructions of the physical therapist, a leader pulled the horse reins in front to control the horse gait, gait velocity, and orient the horse in different directions . All these movements activate the patient's neuromuscular and sensory reactions.

Both groups performed Schroth exercises that are patient-specific asymmetric exercises with rotational breathing methods used for three-dimensional correction. For the first 2 weeks, there were five 1-h long individual sessions during which the participants were trained in their home exercise program. This was followed by 1-h weekly visits and paired with their daily home exercises. These exercises aimed to provide and promote enhanced postural control by using asymmetrical standing postural exercises specifically designed to restore body balance and mobility. During ground exercises, aid pads were used to build pressure for costal protrusions and/or trunk asymmetry correction. Postural correction was facilitated by rotational breathing exercises focusing on the concave side of the thorax. During the therapy sessions, postural correction principles of the Schroth process, axial elongation, deflection, de-rotation, facilitation, stabilization, were used.
There are 2 separate experiments proposed, both of which use repeated-measures designs.

1: Electrocorticography (ECoG) study of visual working memory. Each trial from the behavioral task will start by presenting subjects with two visual images, one each from two of these three categories: faces, words, and outdoor scenes. They will then be cued as to which one they'll be tested on with a recognition probe, and after the first probe the cuing-probing process is repeated. Patients selected for this study will have depth electrodes implanted in the left medial temporal lobe and/or grids covering left occipital, temporal, and/or parietal cortex, and suitability of a patient's data for the final dataset will require that a minimum of one stimulus category can be decoded from them. (The precise minimum number of trials required cannot be calculated a priori, because this requires knowing the signal-to-noise ratio in a dataset, a property that is highly variable in electrocorticography data.)

2. Electrocorticography of spatial selective attention. Each trial from the behavioral task will start by presenting subjects with a white "+" on a screen, with each arm pointing to a potential target location. During each 92-trial block of trials, only two 180-degree opposing locations will ever be cued, with one arm of the "+" turning yellow and the opposing one turning blue, to indicate with 75% validity the location at which an oriented Gabor patch will appear (5 degrees from fixation; cue color mapping counterbalanced), requiring a speeded "R/L" tilt judgment. Orthogonal to cue-color configuration, half of the trials in each block will begin with presentation of an "x" that will rotate by 45 degrees with an unpredictable lag (.5 sec +/- .3). On these trials, the cue-to-target interval (i.e., from rotation to "+" to color-cue onset) will be 750 msec. On trials that begin with the onset of a "+", cue-to-target interval will vary unpredictably between 650, 750, and 850 msec. Decomposition of alpha-band oscillations (brain waves cycling at roughly 10 times per second) into components associated with each location will be derived by filtering the whole-scalp signal with weights from the inverted encoding model trained to encode the four critical locations.